EE88 Cost-Effectiveness of Apixaban Compared to Warfarin, Dabigatran and Rivaroxaban in Patients with Nonvalvular Atrial Fibrillation: Results for High-Risk Patient Subgroups Based on the Aristophanes Real-World Evidence Study
Jun 1, 2024, 00:00
10.1016/j.jval.2024.03.388
https://www.valueinhealthjournal.com/article/S1098-3015(24)00503-5/fulltext
Title :
EE88 Cost-Effectiveness of Apixaban Compared to Warfarin, Dabigatran and Rivaroxaban in Patients with Nonvalvular Atrial Fibrillation: Results for High-Risk Patient Subgroups Based on the Aristophanes Real-World Evidence Study
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(24)00503-5&doi=10.1016/j.jval.2024.03.388
First page :
Section Title :
Open access? :
No
Section Order :
11734